HANMI PHARM. Sustainability Profile
HANMI PHARM, officially known as Hanmi Pharmaceutical Co., Ltd., is a leading player in the global pharmaceutical industry, headquartered in KP. Established in 1973, the company has made significant strides in research and development, particularly in the fields of oncology, diabetes, and autoimmune diseases. With a strong presence in both domestic and international markets, HANMI PHARM is renowned for its innovative drug formulations and advanced biopharmaceuticals. Their core products, including unique oral medications and biologics, set them apart through their efficacy and safety profiles. Recognised for its commitment to quality and innovation, HANMI PHARM has achieved notable milestones, including strategic partnerships and successful product launches that enhance its market position. As a forward-thinking organisation, it continues to contribute to the advancement of healthcare solutions worldwide.
DitchCarbon Score
How does HANMI PHARM.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
HANMI PHARM.'s score of 32 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
HANMI PHARM.'s reported carbon emissions
In 2024, HANMI PHARM. reported total carbon emissions of approximately 930,090 kg CO2e, with Scope 1 emissions accounting for about 295,960 kg CO2e. The previous year, 2023, saw significantly higher emissions, with total emissions reaching approximately 61,238,000 kg CO2e, comprising about 11,520,000 kg CO2e from Scope 1 and about 49,719,000 kg CO2e from Scope 2. Additionally, Scope 3 emissions for 2023 were reported at approximately 82,555,000 kg CO2e, indicating a comprehensive approach to emissions tracking across all scopes. Despite these figures, HANMI PHARM. has not set specific reduction targets or initiatives as part of their climate commitments. The company has not disclosed any Science-Based Targets Initiative (SBTi) reduction targets or other formal climate pledges. This lack of defined targets may reflect a broader industry context where many pharmaceutical companies are still developing robust climate strategies. Overall, while HANMI PHARM. has made strides in emissions reporting, the absence of reduction commitments highlights an area for potential growth in their environmental strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 13,523,000 | 00,000,000 | 00,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 58,287,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 |
How Carbon Intensive is HANMI PHARM.'s Industry?
How Carbon Intensive is HANMI PHARM.'s Location?
HANMI PHARM.'s Scope 3 Categories Breakdown
Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 57% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
HANMI PHARM.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
HANMI PHARM. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
